Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315

The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure

Pitt, B., Zannad, F., Remme, W. J., Cody, R., Castaigne, A., Perez, A., Palensky, J., & Wittes, J. (1999) · New England Journal of Medicine · doi:10.1056/nejm199909023411001 · Cited by 9,214

Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38

(1998) · BMJ · doi:10.1136/bmj.317.7160.703 · Cited by 6,683

Effects of intensive blood-pressure control in type 2 diabetes mellitus

(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001286 · Cited by 3,598

Effect of a multifactorial intervention on mortality in type 2 diabetes

Gæde, P., Lund-Andersen, H., Parving, H.-H., & Pedersen, O. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0706245 · Cited by 3,465

Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial

Patel, A. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61303-8 · Cited by 2,054

Statistics in Medicine — Reporting of Subgroup Analyses in Clinical Trials

Wang, R., Lagakos, S. W., Ware, J. H., Hunter, D. J., & Drazen, J. M. (2007) · New England Journal of Medicine · doi:10.1056/nejmsr077003 · Cited by 1,445

Adaptation of the distal convoluted tubule of the rat. Structural and functional effects of dietary salt intake and chronic diuretic infusion.

Ellison, D. H., Velázquez, H., & Wright, F. S. (1989) · Journal of Clinical Investigation · doi:10.1172/jci113847 · Cited by 294

Effects of Mineralocorticoid Receptor Antagonists on the Risk of Sudden Cardiac Death in Patients With Left Ventricular Systolic Dysfunction

Bapoje, S. R., Bahia, A., Hokanson, J. E., Peterson, P. N., Heidenreich, P. A., Lindenfeld, J. M., Allen, L. A., & Masoudi, F. A. (2013) · Circulation Heart Failure · doi:10.1161/circheartfailure.112.000003 · Cited by 45

Position Paper on the Diagnosis and Treatment of Peripheral Arterial Disease (PAD) in People with Diabetes Mellitus

Balletshofer, B. M., Ito, W. D., Lawall, H., Malyar, N. M., Oberländer, Y., Reimer, P., Rittig, K., & Zähringer, M. (2019) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-1018-9250 · Cited by 18

Sodium Glucose Cotransporter 2 Inhibitors Reduce the Risk of Heart Failure Hospitalization in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Zhang, A., Luo, X., Meng, H., Kang, J., Qin, G., Chen, Y., & Zhang, X. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.604250 · Cited by 16

Usefulness of Sodium-Glucose Cotransporter 2 Inhibitors for Primary Prevention of Heart Failure in Patients With Type 2 Diabetes Mellitus

Arbel, R., Aboalhasan, E., Hammerman, A., & Azuri, J. (2021) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2021.03.040 · Cited by 15

Cost-Effectiveness of Adding Empagliflozin to Standard Treatment for Heart Failure with Preserved Ejection Fraction Patients in China

Lou, Y., Hu, T., & Huang, J. (2022) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-022-00550-9 · Cited by 15

Comparison of Glucagon-Like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter Protein-2 Inhibitors on Treating Metabolic Dysfunction-Associated Steatotic Liver Disease or Metabolic Dysfunction-Associated Steatohepatitis: Systematic Review and Network Meta-Analysis of Randomised Controlled Trials

Xu, R., Liu, B., & Zhou, X. (2024) · Endocrine Practice · doi:10.1016/j.eprac.2024.11.017 · Cited by 16

The optimal blood pressure target in diabetes mellitus: a quest coming to an end?

Papadopoulou, E., Angeloudi, E., Karras, S. Ν., & Sarafidis, P. A. (2018) · Journal of Human Hypertension · doi:10.1038/s41371-018-0079-5 · Cited by 15

Clinical potential of canagliflozin in cardiovascular risk reduction in patients with type 2 diabetes

Skelley, J. W., Carter, B. S., & Roberts, M. Z. (2018) · Vascular Health and Risk Management · doi:10.2147/vhrm.s168472 · Cited by 15

Update on the Cardiovascular Benefits of Sodium-Glucose Co-Transporter-2 Inhibitors: Mechanism of Action, Available Agents and Comprehensive Review of Literature

Abdelmasih, R., Abdelmaseih, R., Thakker, R. A., Faluk, M. A., Ali, A., Alsamman, M., & Hasan, S. M. (2021) · Cardiology Research · doi:10.14740/cr1268 · Cited by 15

Association of Whole Blood Viscosity With Metabolic Syndrome in Type 2 Diabetic Patients: Independent Association With Post-Breakfast Triglyceridemia

Minato, S., Takenouchi, A., Uchida, J., Tsuboi, A., Kurata, M., Fukuo, K., & Kazumi, T. (2017) · Journal of Clinical Medicine Research · doi:10.14740/jocmr2885w · Cited by 15

Possibility of a New Therapeutic Strategy for Left Ventricular Dysfunction in Type 2 Diabetes

Sakamoto, M., Matsutani, D., & Kayama, Y. (2018) · Journal of Clinical Medicine Research · doi:10.14740/jocmr3584w · Cited by 15

Exploiting common aspects of obesity and cancer cachexia for future therapeutic strategies

Molocea, C., Tsokanos, F., & Herzig, S. (2020) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2020.07.006 · Cited by 15

Renal effectiveness and safety of the sodium-glucose cotransporter-2 inhibitors: a population-based cohort study

Alkabbani, W., Zongo, A., Minhas‐Sandhu, J. K., Eurich, D. T., Shah, B. R., Alsabbagh, M. W., & Gamble, J. (2021) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2021-002496 · Cited by 16

The overall benefits of empagliflozin treatment in adult siblings with glycogen storage disease type Ib: one year experience

Bidiuk, J., Gaciong, Z. A., & Sobieraj, P. (2022) · Archives of Medical Science · doi:10.5114/aoms/150029 · Cited by 14

SGLT2 Inhibitors May Restore Endothelial Barrier Interrupted by 25-Hydroxycholesterol

Pawlos, A., Broncel, M., Woźniak, E., Markiewicz, Ł., Piastowska‐Ciesielska, A. W., & Gorzelak‐Pabiś, P. (2023) · Molecules · doi:10.3390/molecules28031112 · Cited by 14

Harnessing the Synergy of SGLT2 Inhibitors and Continuous Ketone Monitoring (CKM) in Managing Heart Failure among Patients with Type 1 Diabetes

Tecce, N., de Alteriis, G., de Alteriis, G., Verde, L., Tecce, M. F., Colao, A., & Muscogiuri, G. (2024) · Healthcare · doi:10.3390/healthcare12070753 · Cited by 15

Alport Syndrome

Chavez, E., Goncalves, S., Rheault, M. N., & Fornoni, A. (2024) · Advances in Kidney Disease and Health · doi:10.1053/j.akdh.2024.02.004 · Cited by 14

Empagliflozin Attenuates Pulmonary Arterial Remodeling Through Peroxisome Proliferator-Activated Receptor Gamma Activation

Lai, Y., Yeh, Y., Huang, Y., Almeida, C. D., Chang, G., Chen, W.-J., & Hsu, H. (2024) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.4c00127 · Cited by 14

Redefining outcomes of ventricular arrhythmia for SGLT2 inhibitor medication in heart failure patients: a meta-analysis of randomized controlled trials

Lin, M., Zhang, S., Zhang, L., Yang, C., Yang, L., Peng, Y., Tan, X., Wen, Q., Fan, X., & Ou, X. (2025) · Systematic Reviews · doi:10.1186/s13643-025-02766-7 · Cited by 14

Effects of Tofogliflozin on Cardiac Function in Elderly Patients With Diabetes Mellitus

Higashikawa, T., Ito, T., Mizuno, T., Ishigami, K., Kohori, M., Mae, K., Usuda, D., Takagi, S., Sangen, R., Saito, A., et al. (2020) · Journal of Clinical Medicine Research · doi:10.14740/jocmr4098 · Cited by 14

Canagliflozin improves risk factors of metabolic syndrome in patients with type 2 diabetes mellitus and metabolic syndrome

Davies, M. J., Merton, K., Vijapurkar, U., Balis, D. A., & Desai, M. G. (2017) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s126291 · Cited by 14

Personalizing Second-Line Type 2 Diabetes Treatment Selection: Combining Network Meta-analysis, Individualized Risk, and Patient Preferences for Unified Decision Support

Choi, S. E., Berkowitz, S. A., Yudkin, J. S., Naci, H., & Basu, S. (2019) · Medical Decision Making · doi:10.1177/0272989x19829735 · Cited by 16

Rationale and design of the expanded combination of evolocumab plus empagliflozin in diabetes: EXCEED-BHS3 trial

Breder, I. S. S., Breder, J. D. S. C., Bonilha, I., Munhoz, D., Kimura-Medorima, S. T., de Oliveira, D. C., do Carmo, H. R. P., Moreira, C., Kontush, A., Zimetti, F., et al. (2020) · Therapeutic Advances in Chronic Disease · doi:10.1177/2040622320959248 · Cited by 14

Predicted Cardiac Hemodynamic Consequences of the Renal Actions of SGLT2i in the DAPA‐HF Study Population: A Mathematical Modeling Analysis

Yu, H., Tang, W., Greasley, P. J., Penland, R. C., Boulton, D. W., & Hallow, K. M. (2020) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.1769 · Cited by 14

Cardiac lipotoxicity and fibrosis underlie impaired contractility in a mouse model of metabolic dysfunction‐associated steatotic liver disease

Badmus, O. O., da Silva, A. A., Li, X., Taylor, L. C., Greer, J. R., Wasson, A. R., McGowan, K., Patel, P. R., & Stec, D. E. (2024) · FASEB BioAdvances · doi:10.1096/fba.2023-00139 · Cited by 13

One or two? Comparison of the cardiorenal effects between combination therapy and monotherapy with SGLT2i or GLP1RA

Zhang, M., Lin, C., Cai, X., Jiao, R., Bai, S., Li, Z., Lv, F., Yang, W., Liu, G., Yang, X., et al. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16078 · Cited by 14

A review of chemical therapies for treating diabetic hypertension

Sarafidis, P. A., Alexandrou, M. E., & Ruilope, L. M. (2017) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2017.1328054 · Cited by 13

Physician experiences with sodium-glucose cotransporter (SGLT2) inhibitors, a new class of medications in type 2 diabetes, and adverse effects

Patakfalvi, L., Brazeau, A., & Dasgupta, K. (2018) · Primary Health Care Research & Development · doi:10.1017/s1463423618000476 · Cited by 13

Long-Term Treatment with Empagliflozin Attenuates Renal Damage in Obese Zucker Rat

Manne, N. D. P. K., Ginjupalli, G. K., Rice, K. M., Arvapalli, R., Graffeo, V. A., Bandarupalli, V. V. K., & Blough, E. R. (2019) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-0815-4908 · Cited by 13

Characterization of the renal cortical transcriptome following Roux-en-Y gastric bypass surgery in experimental diabetic kidney disease

Nair, M., Martin, W. P., Zhernovkov, V., Elliott, J. A., Fearon, N. M., Eckhardt, H., McCormack, J., Godson, C., Brennan, E. P., Marai, M., et al. (2020) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2019-001113 · Cited by 14

Heart Failure With Mid-range or Recovered Ejection Fraction: Differential Determinants of Transition

Margonato, D., Mazzetti, S., Maria, R. D., Gorini, M., Iacoviello, M., Maggioni, A. P., & Mortara, A. (2020) · Cardiac failure review · doi:10.15420/cfr.2020.13 · Cited by 13

Drug utilisation study of antidiabetic medication during 2012‐2019 in Romania

Bucșa, C., Farcas, A. M., Iaru, I., Mogoșan, C., & Rusu, A. (2021) · International Journal of Clinical Practice · doi:10.1111/ijcp.14770 · Cited by 13

Glucagon-Like Peptide 1 Receptor Agonists Versus Sodium-Glucose Cotransporter 2 Inhibitors for Atherosclerotic Cardiovascular Disease in Patients With Type 2 Diabetes

Yanai, H., Adachi, H., Hakoshima, M., & Katsuyama, H. (2023) · Cardiology Research · doi:10.14740/cr1459 · Cited by 14

Effects of Ipragliflozin on Diabetic Nephropathy and Blood Pressure in Patients With Type 2 Diabetes: An Open-Label Study

Ito, D., Ikuma-Suwa, E., Inoue, K., Kaneko, K., Yanagisawa, M., Inukai, K., Noda, M., & Shimada, A. (2016) · Journal of Clinical Medicine Research · doi:10.14740/jocmr2875w · Cited by 13

Empagliflozin attenuates renal damage in diabetic nephropathy by modulating mitochondrial quality control via Prdx3-PINK1 pathway

Guo, C., Zhang, T., Du, L., Yu, K., Zeng, S., Li, M., Chi, Y., & Li, Y. (2025) · Biochemical Pharmacology · doi:10.1016/j.bcp.2025.116821 · Cited by 14

Mild to moderate chronic kidney disease and cardiovascular events in patients with type 2 diabetes mellitus

Lessey, G., Stavropoulos, K., & Papademetriou, V. (2019) · Vascular Health and Risk Management · doi:10.2147/vhrm.s203925 · Cited by 13

Multifunctional agents based on benzoxazolone as promising therapeutic drugs for diabetic nephropathy

Zhang, X., Chen, H., Lei, Y., Zhang, X., Xu, L., Liu, W., Fan, Z., Ma, Z., Yin, Z., Li, L., et al. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113269 · Cited by 12

Nationwide Trends in Dispensing of Sodium Glucose Cotransporter 2 Inhibitors

Fralick, M., Martins, D., Tadrous, M., & Gomes, T. (2022) · The Canadian Journal of Hospital Pharmacy · doi:10.4212/cjhp.v75i2.3066 · Cited by 12

The Determination of Diabetes Utilities, Costs, and Effects Model: A Cost-Utility Tool Using Patient-Level Microsimulation to Evaluate Sensor-Based Glucose Monitoring Systems in Type 1 and Type 2 Diabetes: Comparative Validation

Szafranski, K., de Pouvourville, G., Greenberg, D., Harris, S. B., JENDLE, J. H., Shaw, J. E., Coaquira, J., Poon, Y., & Levrat‐Guillen, F. (2024) · Value in Health · doi:10.1016/j.jval.2024.01.010 · Cited by 12

Practical Considerations for the Use of Subcutaneous Treatment in the Management of Dyslipidaemia

Boccara, F., Dent, R. E., Ruilope, L. M., & Valensi, P. E. (2017) · Advances in Therapy · doi:10.1007/s12325-017-0586-8 · Cited by 14

Efficacy and Clinical Value of Liraglutide for Treatment of Diabetes Mellitus Complicated by Non-Alcoholic Fatty Liver Disease

Zhang, Z., Qi, Y., Kong, W., Jin, Q., Wang, X., Dong, Y., Wang, Y., & Li, H. (2018) · Medical Science Monitor · doi:10.12659/msm.911062 · Cited by 14

Heart Failure Therapies for the Prevention of HER2-Monoclonal Antibody-Mediated Cardiotoxicity: A Systematic Review and Meta-Analysis of Randomized Trials

Brown, L. J., Meredith, T., Yu, J., Patel, A. A., Neal, B. C., Arnott, C. G., & Lim, E. (2021) · Cancers · doi:10.3390/cancers13215527 · Cited by 12

Predictors Associated with Type 2 Diabetes Mellitus Complications over Time: A Literature Review

Elhefnawy, M. E., Ghadzi, S. M. S., & Harun, S. N. (2022) · Journal of Vascular Diseases · doi:10.3390/jvd1010003 · Cited by 17

Dipeptidyl peptidase 4 inhibitors, sodium glucose cotransporter 2 inhibitors, and glucagon-like peptide 1 receptor agonists do not worsen diabetic macular edema

Phu, A., Banghart, M., Bahrainian, M., Liu, T. Y. A., Wolf, R. M., & Channa, R. (2024) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2024.108808 · Cited by 11

Multiple Benefits of Empagliflozin in PCOS: Evidence from a Preclinical Rat Model

Rakic, D., Jakovljevic, V. L., Zivkovic, V., Uzelac, J. J., Jovic, N., Muric, M. D., Pindović, B., Dimitrijević, A., Arsenijević, P. S., Rakic, J., et al. (2024) · Pathophysiology · doi:10.3390/pathophysiology31040041 · Cited by 11

Evaluation and comparison of efficacy and safety of tirzepatide, liraglutide and SGLT2i in patients with type 2 diabetes mellitus: a network meta-analysis

Teng, Y., Fan, X., Yu, R., & Yang, X. (2024) · BMC Endocrine Disorders · doi:10.1186/s12902-024-01805-z · Cited by 13

The role of intracoronary imaging in translational research

Montarello, N. J., Nelson, A. J., Verjans, J. W. H., Nicholls, S. J., & Psaltis, P. J. (2020) · Cardiovascular Diagnosis and Therapy · doi:10.21037/cdt-20-1 · Cited by 12

National Asthma Education and Prevention Program 2020 Guidelines: What’s Important for Primary Care

Murphy, M. (2021) · The Journal of Family Practice · doi:10.12788/jfp.0219 · Cited by 14

Proteomic Analysis and Sex-Specific Changes in Chronically Ischemic Swine Myocardium Treated with Sodium-Glucose Cotransporter-2 Inhibitor Canagliflozin

Harris, D. D., Sabe, S. A., Broadwin, M., Stone, C., Malhotra, A., Xu, C., Sabra, M., Abid, M. R., & Sellke, F. W. (2024) · Journal of the American College of Surgeons · doi:10.1097/xcs.0000000000001021 · Cited by 11

Differential pharmacology and clinical utility of empagliflozin in type 2 diabetes

Davis, S. N., & Munir, K. M. (2016) · Clinical Pharmacology Advances and Applications · doi:10.2147/cpaa.s77754 · Cited by 11

Effect of Canagliflozin on Heart Function Involving Ketone Bodies in Patients with Type 2 Diabetes

Kutoh, E., & Hayashi, J. (2018) · Drug Research · doi:10.1055/a-0748-5745 · Cited by 11

Current European guidelines on arterial hypertension: new positions and unsolved issues

Кобалава, Ж. Д., Kolesnik, E. L., & Троицкая, Е. А. (2019) · Clinical pharmacology and therapy · doi:10.32756/0869-5490-2019-2-7-18 · Cited by 11

A Case of Euglycemic Diabetic Ketoacidosis in a Patient With Type 2 Diabetes Mellitus and COVID-19

Morrison, N. J., Barnett, K., Tantum, J., Morrison, H., & Whalen, M. (2020) · Cureus · doi:10.7759/cureus.12029 · Cited by 11

Canagliflozin in the treatment of type 2 diabetes: an evidence-based review of its place in therapy

Karagiannis, T., Bekiari, E., & Τσάπας, Α. (2017) · Core evidence · doi:10.2147/ce.s109654 · Cited by 11

Renal Oxygen Demand and Nephron Function: Is Glucose a Friend or Foe?

Gronda, E., Iacoviello, M., Palazzuoli, A., Benevenuto, M., Gabrielli, D., & Arduini, A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24129957 · Cited by 13

Proteomic Profiling of SGLT-2 Inhibitor Canagliflozin in a Swine Model of Chronic Myocardial Ischemia

Harris, D. D., Sabe, S. A., Broadwin, M., Stone, C., Xu, C., Hu, J., Kanuparthy, M., Abid, M. R., & Sellke, F. W. (2024) · Biomedicines · doi:10.3390/biomedicines12030588 · Cited by 10

Recent advances associated with cardiometabolic remodeling in diabetes-induced heart failure

Sharma, G., Chaurasia, S. S., Carlson, M. A., & Mishra, P. K. (2024) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00539.2024 · Cited by 10

Progress in heart failure treatment in Germany

Luedde, M., Spehlmann, M. E., & Frey, N. (2018) · Clinical Research in Cardiology · doi:10.1007/s00392-018-1317-0 · Cited by 10

Effect of Dapagliflozin on Serum Uric Acid Levels in Patients with Advanced Chronic Kidney Disease

Mori, D., Kobayashi, M., Wada, M., Tokuchi, M., Misegawa, S., Saito, R., Nomi, H., Haga, R., Nagatoya, K., & Yamauchi, A. (2023) · Internal Medicine · doi:10.2169/internalmedicine.1828-23 · Cited by 10

SGLT-2 inhibitors in heart failure and chronic kidney disease: A review for internists

Jaswaney, R., Sokoloff, S., Rakita, V., & Rubin, D. J. (2024) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.91a.23093 · Cited by 12

Pharmacologic Management for Heart Failure and Emerging Therapies

Kim, D. H., Chien, F.-J., & Eisen, H. J. (2017) · Current Cardiology Reports · doi:10.1007/s11886-017-0899-x · Cited by 11

Antihyperglycemic Medications and Cardiovascular Risk Reduction

Anderson, S. L., & Marrs, J. C. (2017) · touchREVIEWS in Endocrinology · doi:10.17925/ee.2017.13.02.86 · Cited by 10

Postoperative Euglycemic Diabetic Ketoacidosis and Encephalopathy Related to SGLT-2 Inhibitors: A Case Report and Discussion of Diabetes Treatment and “Sweet Pee Encephalopathy” in Perioperative Hospital Management

Mackintosh, C., Tewari, A., Siegel, J. L., Wang, R. D., & Freeman, W. (2019) · The Neurohospitalist · doi:10.1177/1941874419835035 · Cited by 10

Effect of Dapagliflozin on Cardiac Function and Metabolic and Hormonal Responses to Exercise

Herring, R. A., Parsons, I., Shojaee‐Moradie, F., Stevenage, M., Jackson, N., MANDERS, R. J. F., Umpleby, A. M., Fielding, B. A., Davies, M. J., & Russell-Jones, D. L. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac617 · Cited by 10

Prevalence of genitourinary infection in diabetic patients treated with SGLT 2 inhibitors

Shrikrishna, A., & Bhat, A. (2023) · African Health Sciences · doi:10.4314/ahs.v23i1.29 · Cited by 10

Advances in the treatment of type 2 diabetes: impact of dulaglutide

Thompson, A., & Trujillo, J. M. (2016) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s75452 · Cited by 12

Glucose-lowering treatment in cardiovascular and peripheral artery disease

Suades, R., Cosentino, F., & Badimón, L. (2018) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2018.03.001 · Cited by 11

Sodium-glucose cotransporter-2 inhibitors improve liver enzymes in patients with co-existing non-alcoholic fatty liver disease: a systematic review and metanalysis

Amjad, W., Malik, A., Qureshi, W., Dennis, B. B., Mumtaz, M., Haider, R., Jamal, S. M., Jaura, F., & Ahmed, A. (2022) · Gastroenterology Review · doi:10.5114/pg.2021.112365 · Cited by 11

A review of potential mechanisms and uses of SGLT2 inhibitors in ischemia-reperfusion phenomena

Quentin, V., Singh, M., & Nguyen, L. S. (2022) · World Journal of Diabetes · doi:10.4239/wjd.v13.i9.683 · Cited by 9

Masked anemia and hematocrit elevation under sodium glucose transporter inhibitors: findings from a large real-world study

Schwarz, Y., Klein, P., & Lev-Shalem, L. (2023) · Acta Diabetologica · doi:10.1007/s00592-023-02174-0 · Cited by 9

Guidelines on primary healthcare for type 2 diabetes in China, 2025

Jia, W., Zhu, D., Guo, L., Chen, L., Cai, C., & Song, J. (2025) · Family Medicine and Community Health · doi:10.1136/fmch-2025-003765 · Cited by 9

Innovative Diabetes Therapies and Impact on Peripheral and Autonomic Diabetic Neuropathies: A State-of-the-Art Review

Vekić, J., Zeljković, A., Maggio, V., Rizzo, M., & Medenica, S. (2026) · Diabetes Therapy · doi:10.1007/s13300-025-01828-2 · Cited by 10

Sodium–glucose cotransporter 2 inhibitors in horses—Magic bullet or latest fad?

Sundra, T., Lester, G. D., Rossi, G., & Rendle, D. I. (2023) · Equine Veterinary Journal · doi:10.1111/evj.13944 · Cited by 9

Cardiovascular protective effect of sodium-glucose cotransporter 2 inhibitors on patients with acute coronary syndrome and type 2 diabetes mellitus: a retrospective study

Chen, J., Chang, J., Shi, Q., Li, X., Wang, L., & Zhao, H. (2023) · BMC Cardiovascular Disorders · doi:10.1186/s12872-023-03542-y · Cited by 9

Comparative efficacy and safety of SGLT2is and ns-MRAs in patients with diabetic kidney disease: a systematic review and network meta-analysis

Yang, S., Zhao, X., Zhang, J., Liu, H., Wang, Y., & Wang, Y.-G. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1429261 · Cited by 8

The effects of Dapagliflozin in a real-world population of HFrEF patients with different hemodynamic profiles: worse is better

Loria, F., Mone, P., Rispoli, A., Fonzo, R. D., Masarone, D., Mancusi, C., Correale, M., Vitullo, A., Granatiero, M., Mazzeo, P., et al. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02515-5 · Cited by 9

A narrative review of low-dose rivaroxaban in patients with atherothrombotic cardiovascular disease: vascular protection beyond anticoagulation

Rocha, B. M. L., Cunha, G., & Aguíar, C. (2021) · Cardiovascular Diagnosis and Therapy · doi:10.21037/cdt-20-859 · Cited by 11

Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Hepatic Fibrosis in Patients With Type 2 Diabetes: A Chart-Based Analysis

Katsuyama, H., Hakoshima, M., Iijima, T., Adachi, H., & Yanai, H. (2020) · Journal of Endocrinology and Metabolism · doi:10.14740/jem632 · Cited by 9

Metformin Use in Patients With Historical Contraindications

Lipska, K. (2017) · Annals of Internal Medicine · doi:10.7326/m16-2712 · Cited by 10

Documento de consenso sobre nuevas terapias para retrasar la progresión de la enfermedad renal crónica con énfasis en los iSGLT-2: implicaciones para Latinoamérica

Obrador, G. T., Álvarez-Estévez, G., Bellorín-Font, E., Bonanno-Hidalgo, C., Clavero, R., Correa‐Rotter, R., Diná-Batlle, E., Morales, L., Orozco, R., Ortiz, F., et al. (2024) · Nefrología Latinoamericana · doi:10.24875/nefro.m24000037 · Cited by 12

The influence of SGLT-2 inhibitors on lipid profiles in heart failure patients: a systematic review and meta-analysis

Meybodi, S. M. (2024) · American Journal of Cardiovascular Disease · doi:10.62347/aapz2726 · Cited by 8

Habitual Hot-Tub Bathing and Cardiovascular Risk Factors in Patients With Type 2 Diabetes Mellitus: A Cross-Sectional Study

Katsuyama, H., Hakoshima, M., Adachi, H., Masui, Y., Sako, A., Inokuma, S., & Yanai, H. (2022) · Cardiology Research · doi:10.14740/cr1371 · Cited by 8

Cost-effectiveness of empagliflozin for the treatment of heart failure with reduced ejection fraction in China

Sang, H., Wan, Y., Ma, Z., Zhang, S., & Zhao, Q. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.1022020 · Cited by 8

A Review of the Safety and Efficacy of Bexagliflozin for the Management of Type 2 Diabetes

Cowart, K., Coon, S. A., & Carris, N. W. (2023) · Annals of Pharmacotherapy · doi:10.1177/10600280231190443 · Cited by 9

A practical approach to hyperinsulinaemia in horses with equine metabolic syndrome

Sundra, T., Rossi, G., Rendle, D. I., & Lester, G. D. (2024) · Equine Veterinary Education · doi:10.1111/eve.13938 · Cited by 8

Diabetes destiny in our hands: Achieving metabolic karma

Kalra, S., Ved, J., & Baruah, M. (2017) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/ijem.ijem_571_16 · Cited by 8

Updates in pharmacotherapy of heart failure with reduced ejection fraction

Espinoza, C., Alkhateeb, H., & Siddiqui, T. (2021) · Annals of Translational Medicine · doi:10.21037/atm-20-4640 · Cited by 9

Efficacy and Safety of Naproxen for Acute Pain

Weisman, S. R. (2020) · The Journal of Family Practice · doi:10.12788/jfp.0064 · Cited by 8

Combination Therapy of Alpha-Glucosidase Inhibitor, Thiazolidinedione and Sodium Glucose Co-Transporter-2 Inhibitor in Japanese Type 2 Diabetes Patients

Kusunoki, M., Wakazono, N., Tsutsumi, K., Oshida, Y., & Miyata, T. (2020) · Journal of Endocrinology and Metabolism · doi:10.14740/jem708 · Cited by 8

Progress in the management of patients with diabetes and chronic kidney disease

Garcia, L. P., Thomas, S. S., Rajesh, H., & Navaneethan, S. D. (2022) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000000811 · Cited by 9

How to position sodium-glucose co-transporter 2 inhibitors in the management of diabetes in acromegaly patients

Zaina, A., Prencipe, N., Golden, E., Berton, A. M., Arad, E., Ali, A., Shehadeh, J., Kassem, S., & Ghigo, E. (2023) · Endocrine · doi:10.1007/s12020-023-03352-4 · Cited by 8

Management Protocols of stable coronary artery disease in India: Executive summary

Mishra, S., Ray, S., Dalal, J. J., Sawhney, J. P. S., Ramakrishnan, S., Nair, T., Iyengar, S., & Bahl, V. K. (2016) · Indian Heart Journal · doi:10.1016/j.ihj.2016.11.318 · Cited by 8

Metformin combined with dipeptidyl peptidase-4 inhibitors or metformin combined with sulfonylureas in patients with type 2 diabetes: A real world analysis of the South Korean national cohort

Cho, Y. Y., & Cho, S. (2018) · Metabolism · doi:10.1016/j.metabol.2018.03.009 · Cited by 8

Empagliflozin in the treatment of heart failure and type 2 diabetes mellitus: Evidence from several large clinical trials

Liang, B., & Gu, N. (2022) · International Journal of Medical Sciences · doi:10.7150/ijms.72772 · Cited by 8

The effect of the four pharmacological pillars of heart failure on haemoglobin level

Hullon, D., Taherifard, E., & AlSaraireh, T. H. (2024) · Annals of Medicine and Surgery · doi:10.1097/ms9.0000000000001773 · Cited by 7

Multivariate Analysis of the Determinants of Total Mortality in the European Union with Focus on Fat Intake, Diabetes, Myocardial Infarction, Life Expectancy, and Preventable Mortality: A Panel Data Fixed-Effects Panel Data Model Approach

Stanciu, S. M., Rusu, E., Jinga, M., Ursu, C. G., Stanciu, R. I., Miricescu, D., Antohi, V. M., & Barbu, E. (2024) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd11100328 · Cited by 7

Empagliflozin Reverses Oxidized LDL-Induced RECK Suppression, Cardiotrophin-1 Expression, MMP Activation, and Human Aortic Smooth Muscle Cell Proliferation and Migration

Chandrasekar, B., Mummidi, S., DeMarco, V. G., & Higashi, Y. (2023) · Mediators of Inflammation · doi:10.1155/2023/6112301 · Cited by 7

Cardiac Reverse Remodelling by Imaging Parameters with Recent Changes to Guideline Medical Therapy in Heart Failure

Kodsi, M. H., Makarious, D., Gan, G. C. H., Choudhary, P., & Thomas, L. (2023) · ESC Heart Failure · doi:10.1002/ehf2.14555 · Cited by 7

Dose modification of antidiabetic agents in patients with type 2 diabetes mellitus and heart failure

Sharma, D., Asirvatham, A. J., & Singh, P. (2017) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/ijem.ijem_442_16 · Cited by 7

Efeito da empagliflozina para além do controlo glicémico: benefício cardiovascular em doentes com DMT2 e doença cardiovascular estabelecida

Monteiro, P. F., Aguíar, C., Matos, P., Silva‐Nunes, J., Birne, R., Branco, P. Q., Calado, J., Melo, M., & Polónia, J. J. (2019) · Revista Portuguesa de Cardiologia · doi:10.1016/j.repc.2019.02.008 · Cited by 9

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes

Baglioni, P. (2019) · New England Journal of Medicine · doi:10.1056/nejmc1902837 · Cited by 324

Cardiovascular Outcomes and Safety of Empagliflozin in Patients With Type 2 Diabetes Mellitus and Peripheral Artery Disease: A Subanalysis of EMPA-REG OUTCOME

Verma, S., Mazer, C. D., Al-Omran, M., Inzucchi, S. E., Fitchett, D., Hehnke, U., George, J. T., & Zinman, B. (2018) · Circulation · doi:10.1161/circulationaha.117.032031 · Cited by 166

Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes mellitus. Dr. Hertzel Gerstein in an interview with Dr. Roman Jaeschke

Gerstein, H. C., & Jaeschke, R. (2016) · Polskie Archiwum Medycyny Wewnętrznej · doi:10.20452/pamw.3612 · Cited by 3

Empagliflozin reduces cardiovascular events and mortality in type 2 diabetes

Guthrie, R. M. (2016) · Postgraduate Medicine · doi:10.1080/00325481.2016.1174566 · Cited by 3

Reducing type 2 diabetes mortality: empagliflozin study

Pezalla, E. J. (2015) · Healthcare executive